Kendy “courtesy” letter
This article was originally published in The Tan Sheet
FDA does not believe that the meaning of the "help maintain normal blood cholesterol levels" structure/function claim "limits the meaning of the claim to only effects on already normal cholesterol levels," the agency tells Kendy USA (Palatine, Ill.) in a recent exchange regarding a structure/function claim submission. Rather, it "includes effects on preventing elevations of cholesterol levels outside of the normal range and reduction of elevated cholesterol into the normal range." Kendy had maintained that since there was no reference to coronary heart disease and that the claim was not specific to reducing high cholesterol levels, the claim was appropriate...
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.